Your browser does not support JavaScript capabilities, which maybe required to display this page properly.


PDF FormatRequires Adobe Acrobat Reader

Table 6.6c

Immunosuppression Use for Induction by Steroid Use at Discharge, 2004 to 2008

Recipients with Pancreas Transplant Alone (PTA) Transplants

  No Steroids Used for Maintenance Steroids Used for Maintenance
N % N %
Functioning Graft with Immunosuppression Info at Discharge 410 100.0% 477 100.0%
Induction Drugs        
Atgam/NRATG/NRATS 5 1.2% 4 0.8%
OKT3 4 1.0% 13 2.7%
Thymoglobulin 234 57.1% 164 34.4%
Zenapax 9 2.2% 58 12.2%
Simulect 5 1.2% 18 3.8%
Campath 158 38.5% 63 13.2%
Rituximab 17 4.1% 3 0.6%
No Induction Drug Reported 49 12.0% 174 36.5%


Source: OPTN/SRTR Data as of May 4, 2009.

Includes patients with a functioning graft at discharge.

Steroids used for induction are not counted.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.



PDF FormatRequires Adobe Acrobat Reader